Reuters exclusively reported that US medical device maker Edwards Lifesciences, a global leader in its field, was the target of an EU antitrust raid a week ago on concerns that it may have abuse its market power. Shares in Edwards Lifesciences shed 2.5% in pre-market trade on the Reuters story. The company, which can face fines up to 10% of its global turnover if found guilty of breaching EU antitrust rules and an order to change its business practices, subsequently confirmed that it had been raided.